Advanced search
1 file | 3.06 MB Add to list

Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium : a BelSACI-Abeforcal-EUFOREA statement

Author
Organization
Abstract
Allergic rhinitis (AR) affects 23-30% of the European population with equal prevalence reported in Belgium. Despite guidelines on the correct use of effective treatment, up to 40% of AR patients remain uncontrolled. Allergen immunotherapy (AIT) has been shown to improve the level of control up to 84% of patients being controlled by AIT. Recently, new guidelines for AIT have been published, supporting the clinical evidence for effectiveness of various subcutaneous and sublingual products for AIT in patients who are allergic to airborne allergens. AIT in AR patients not only reduces nasal and/or ocular symptoms but also induces tolerance and has preventive potential. Adoption of AIT into daily clinical practice in Belgium and other European countries is hampered primarily by reimbursement issues of each of the single products but also by several patient-and physician-related factors. Patients need to be better informed about the effectiveness of AIT and the different routes of administration of AIT. Physicians dealing with AR patients should inform patients on tolerance-inducing effects of AIT and are in the need of a harmonized and practical guide that supports them in selecting eligible patients for AIT, in choosing evidence-based AIT products and in following treatment protocols with proven efficacy. Therefore, a stepwise and holistic approach is needed for better adoption of AIT in the real-life setting in Belgium.
Keywords
Allergic rhinitis, Asthma, Allergen-specific immunotherapy, Belgium, QUALITY-OF-LIFE, NONALLERGIC RHINITIS, MOBILE TECHNOLOGY, WORK PRODUCTIVITY, IMPACT, PREVALENCE, MANAGEMENT, RHINOCONJUNCTIVITIS, GUIDELINES, SYMPTOMS

Downloads

  • 2019- Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 3.06 MB

Citation

Please use this url to cite or link to this publication:

MLA
Hellings, PW et al. “Stepwise Approach Towards Adoption of Allergen Immunotherapy for Allergic Rhinitis and Asthma Patients in Daily Practice in Belgium : a BelSACI-Abeforcal-EUFOREA Statement.” CLINICAL AND TRANSLATIONAL ALLERGY 9 (2019): n. pag. Print.
APA
Hellings, P., Pugin, B., Mariën, G., Bachert, C., Breynaert, C., Bullens, D., Ceuppens, J., et al. (2019). Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium : a BelSACI-Abeforcal-EUFOREA statement. CLINICAL AND TRANSLATIONAL ALLERGY, 9.
Chicago author-date
Hellings, PW, B Pugin, G Mariën, Claus Bachert, C Breynaert, DM Bullens, JL Ceuppens, et al. 2019. “Stepwise Approach Towards Adoption of Allergen Immunotherapy for Allergic Rhinitis and Asthma Patients in Daily Practice in Belgium : a BelSACI-Abeforcal-EUFOREA Statement.” Clinical and Translational Allergy 9.
Chicago author-date (all authors)
Hellings, PW, B Pugin, G Mariën, Claus Bachert, C Breynaert, DM Bullens, JL Ceuppens, G Clement, T Cox, D Ebo, Philippe Gevaert, S Halewyck, V Hox, K Ladha, R Jacobs, P Rombaux, R Schrijvers, K Speleman, X Van der Brempt, L Van Gerven, O Vanderveken, B Verhaeghe, K Vierstraete, S Vlaminck, J-B Watelet, J Bousquet, and SF Seys. 2019. “Stepwise Approach Towards Adoption of Allergen Immunotherapy for Allergic Rhinitis and Asthma Patients in Daily Practice in Belgium : a BelSACI-Abeforcal-EUFOREA Statement.” Clinical and Translational Allergy 9.
Vancouver
1.
Hellings P, Pugin B, Mariën G, Bachert C, Breynaert C, Bullens D, et al. Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium : a BelSACI-Abeforcal-EUFOREA statement. CLINICAL AND TRANSLATIONAL ALLERGY. 2019;9.
IEEE
[1]
P. Hellings et al., “Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium : a BelSACI-Abeforcal-EUFOREA statement,” CLINICAL AND TRANSLATIONAL ALLERGY, vol. 9, 2019.
@article{8609378,
  abstract     = {Allergic rhinitis (AR) affects 23-30% of the European population with equal prevalence reported in Belgium. Despite guidelines on the correct use of effective treatment, up to 40% of AR patients remain uncontrolled. Allergen immunotherapy (AIT) has been shown to improve the level of control up to 84% of patients being controlled by AIT. Recently, new guidelines for AIT have been published, supporting the clinical evidence for effectiveness of various subcutaneous and sublingual products for AIT in patients who are allergic to airborne allergens. AIT in AR patients not only reduces nasal and/or ocular symptoms but also induces tolerance and has preventive potential. Adoption of AIT into daily clinical practice in Belgium and other European countries is hampered primarily by reimbursement issues of each of the single products but also by several patient-and physician-related factors. Patients need to be better informed about the effectiveness of AIT and the different routes of administration of AIT. Physicians dealing with AR patients should inform patients on tolerance-inducing effects of AIT and are in the need of a harmonized and practical guide that supports them in selecting eligible patients for AIT, in choosing evidence-based AIT products and in following treatment protocols with proven efficacy. Therefore, a stepwise and holistic approach is needed for better adoption of AIT in the real-life setting in Belgium.},
  articleno    = {1},
  author       = {Hellings, PW and Pugin, B and Mariën, G and Bachert, Claus and Breynaert, C and Bullens, DM and Ceuppens, JL and Clement, G and Cox, T and Ebo, D and Gevaert, Philippe and Halewyck, S and Hox, V and Ladha, K and Jacobs, R and Rombaux, P and Schrijvers, R and Speleman, K and Van der Brempt, X and Van Gerven, L and Vanderveken, O and Verhaeghe, B and Vierstraete, K and Vlaminck, S and Watelet, J-B and Bousquet, J and Seys, SF},
  issn         = {2045-7022},
  journal      = {CLINICAL AND TRANSLATIONAL ALLERGY},
  keywords     = {Allergic rhinitis,Asthma,Allergen-specific immunotherapy,Belgium,QUALITY-OF-LIFE,NONALLERGIC RHINITIS,MOBILE TECHNOLOGY,WORK PRODUCTIVITY,IMPACT,PREVALENCE,MANAGEMENT,RHINOCONJUNCTIVITIS,GUIDELINES,SYMPTOMS},
  language     = {eng},
  pages        = {7},
  title        = {Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium : a BelSACI-Abeforcal-EUFOREA statement},
  url          = {http://dx.doi.org/10.1186/s13601-019-0243-1},
  volume       = {9},
  year         = {2019},
}

Altmetric
View in Altmetric